Quel est le prix pour Ortin Laboratories Limited (ORTINLAB)

Le prix pour Ortin Laboratories Limited (ORTINLAB) est $0.2488447

Quelle est la capitalisation boursière pour Ortin Laboratories Limited (ORTINLAB)

La capitalisation boursière pour Ortin Laboratories Limited (ORTINLAB) est $2.01M

Ortin Laboratories Limited (ORTINLAB) Ratio P/S

Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad, India, in 1986, is engaged in the manufacturing and commercialization of a diverse range of medicines, drugs, and chemical intermediates. The company provides a wide array of pharmaceutical formulations, presented as tablets, capsules, syrups, and dry powders. These products target various therapeutic domains such as metabolic diseases (e.g., anti-diabetics), allergic reactions, infections (including broad-spectrum antibiotics and antifungals like quinolones, penicillins, cephalosporins, macrolides, and antifungals), pain management and fever reduction (analgesics and antipyretics), cardiovascular ailments (anti-anginal and cardiovascular products), digestive system disorders (antacids and anti-ulcerants), neurological and psychiatric conditions (sedatives, tranquilizers, psychiatry products), and nutritional supplementation (like vitamins, calcium, iron, and protein supplements). Specialized offerings also include anti-retroviral, anti-arthritic, anti-helminthic, anti-spasmodic, gynaec, appetite stimulators, and chemotherapeutic preparations. In addition to finished pharmaceuticals, Ortin produces active pharmaceutical ingredient (API) intermediates for applications such as anti-retrovirals, anti-diabetics, pain and fever medications, antibiotics, antifungals, antacids, anti-malarials, and anti-ulcerants. Its manufacturing capabilities also extend to fine chemicals and Grignard/alkali metal compounds. The company offers specialized services covering process development and characterization, analytical research, assay development, and product characterization. It also contributes to diagnostics through the development of rapid flow kits, assays, and reagents. Ortin Laboratories undertakes long-term contracts for the production of intermediates and the creation of novel APIs. Moreover, it actively functions as a merchant exporter of its finished pharmaceutical products.

Année	Ratio P/S	Changez
2026 (TTM)	127.84	1,703.06%
2024	7.09	198.89%
2023	2.37	6.17%
2022	2.23	-27.83%
2021	3.09	5,013.22%
2020	0.06	-59.23%
2019	0.15	-62.26%
2018	0.39	-47.23%
2017	0.75	1.40%
2016	0.73	30.42%
2015	0.56	44.31%
2014	0.39	3.44%
2013	0.38	45.71%
2012	0.26	-26.61%
2011	0.35	130.96%
2010	0.15	-5.15%
2009	0.16	-2.25%
2008	0.16	0.00%

Année

Ratio P/S

Changez

2026 (TTM)

127.84

1,703.06%

2024

7.09

198.89%

2023

2.37

6.17%

2022

2.23

-27.83%

2021

3.09

5,013.22%

2020

0.06

-59.23%

2019

0.15

-62.26%

2018

0.39

-47.23%

2017

0.75

1.40%

2016

0.73

30.42%

2015

0.56

44.31%

2014

0.39

3.44%

2013

0.38

45.71%

2012

0.26

-26.61%

2011

0.35

130.96%

2010

0.15

-5.15%

2009

0.16

-2.25%

2008

0.16

0.00%

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	7.73	-93.95%	IN

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays